Stop STALLING Act
Click any stage to learn more about the legislative process.
Topic: Health
Sponsor: Sen. Klobuchar, Amy [D-MN] (D) - MN
Summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Legislative Subjects
Administrative remedies; Business ethics; Civil actions and liability; Competition and antitrust; Department of Health and Human Services; Drug safety, medical device, and laboratory regulation; Food and Drug Administration (FDA); Health; Licensing and registrations; Prescription drugs; Public participation and lobbying
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
2025-04-10
Ask about this bill
Ask questions about this bill. The AI can look up referenced laws and statutes to provide context.
What existing laws does this bill amend?
What are the main provisions of this bill?
Who would be affected by this legislation?